MOS Prebiotic Potential in Older Adults

The Prebiotic Potential of a Yeast Cell Wall Fraction Containing Mannooligosaccharides and β-glucans.

Status

Active, not recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05939336

Enrollment

Registered

2023-07-11

Start date

2023-08-01

Completion date

2026-06-30

Last updated

2026-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Healthy

Brief summary

Mannooligosaccharides (MOS) derived from baker's yeast may have prebiotic properties such as improving gastrointestinal function. The aims of this study are to determine the effect of MOS on gastrointestinal function and symptoms and fecal microbiota in older adults.

Detailed description

Novel prebiotics with specific microbiome targets and without adverse gastrointestinal symptoms are needed for the exploration of health benefits. This is a 3-week, open-label pilot study designed to evaluate the effect of 15 g per day of yeast-derived mannooligosaccharides on gastrointestinal symptoms, stool frequency, fecal microbiome, and urinary metabolites.

Interventions

DIETARY_SUPPLEMENTMannooligosaccharides yeast extract

15 g per day of mannooligosaccharide yeast extract.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

50 Years to 99 Years

Healthy volunteers

Yes

Inclusion criteria

* Adults 50-99 years of age. * Able to provide written informed consent in English. * Willingness to complete all study procedures * Healthy or diagnoses with Parkinson's or multiple system atrophy

Exclusion criteria

* Yeast allergy. * Self-reported kidney disease. * Elite athletes or long-distance runners. * Use of antibiotic drugs (e.g., neomycin, rifaximin) within 1 month of the screening visit. * Current use of laxatives or antidiarrheal medications. * Use of other investigational products within 3 months of the screening visit. * Previously or currently being treated for any intestinal disease or condition, including IBS, Crohn's disease, ulcerative colitis, celiac disease, or gastrointestinal cancer (self-report). * Previous gastrointestinal surgery (e.g., gastric bypass, fundoplication, bowel resection) * Current cancer treatment * Currently pregnant

Design outcomes

Primary

Measure	Time frame	Description
Mean daily rating of gastrointestinal symptoms	14 days	Change from baseline mean sum of daily mean rating from 0 (no symptom) to 3 (severe symptoms)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026